Pall Life Sciences wins BPI 2016 Best Downstream Application Award
Cadence Acoustic Separator system is a novel single-use solution for the clarification of cell culture bioprocess fluids.
Pall Life Sciences, a division of Pall Corporation,has won the BioProcess International (BPI) Award for best downstream processing application for the Cadence Acoustic Separator. Celebrated bi-annually since 2012, the BPI Awards are hosted during the BioProcess International Conference in Boston, MA. The awards exist to celebrate outstanding individual and team achievements that allow the industry to deliver better, more effective treatments to a global patient base.
Based on acoustic wave separation technology licensed from FloDesign Sonics, the Cadence Acoustic Separator was launched in early 2016 as a novel single-use solution for the clarification of cell culture bioprocess fluids. The system is a robust platform technology that enables continuous cell separation without centrifugation and dramatically reduced filtration steps for cost-effective preconditioning of the clarified cell culture fluid for downstream processes. The technology can also be fully integrated with Pall’s portfolio of continuous downstream bioprocessing technologies.
“We are honored by the recognition of the Cadence Acoustic Separator in 2016, but it is particularly exciting to win this award,” said Michael Egholm, VP & General Manager of Pall Biopharmaceuticals. “We first introduced the concept of acoustic wave separation for biopharmaceutical applications at last year’s BPI 2015 conference, with the intention of launching in 2016. Thank you to my team, and the team at FloDesign Sonics for partnering with us to develop and launch such a game-changing technology.”
Earlier this year, the Cadence Acoustic Separator technology was awarded second prize for Innovation in an open vote on submitted posters at the Recovery of Biological Products XVII Conference in Bermuda, as well as featured in Pharmaceutical Manufacturing as a 2016 Star Innovation.
The Cadence Acoustic Separator technology is on display in booth 521 at BPI 2016 this week, among a portfolio of enabling Pall Life Sciences technologies. The displays demonstrate scale up for the clarification application, and a process development approach for perfusion with the AWS technology. Both applications are set to be launched in 2017.
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance